Group | Malaria Vaccines

The RTS,S vaccine candidate produced by GlaxoSmithKline (GSK) Biologicals was tested in a Phase 2 trial completed by Ifakara Health Institute (IHI) and Swiss TPH in 2008. That trial showed that co-administration with EPI-vaccines does not affect the safety and immunogenicity of malaria and EPI vaccines and results in substantial and consistent protection in infants.

A recently completed Phase 3 trial undertaken at the IHI’s Bagamoyo branch, as well as in 10 other African centres and including 16'000 infants and small children, demonstrated a 56% protection rate against malaria episodes and a 34% reduction in severe malaria incidence. Our group is also involved in a number of other trials of vaccine candidates, as well as in the immunological study of the vaccine’s responses.

Marcel Tanner

Marcel Tanner, Professor, PhD, Epidemiologist, MPH